AI-powered OCT skin imaging enables fast and reliable BCC visualization and measurement

The new VivoSight AI system rapidly and reliably identifies BCC image markers, simplifying and speeding assessment of treatment efficacy throughout your NMSC treatment research.

  • High definition 3D scan in just 15 seconds
  • AI powered BCC image markers placed in real-time
  • Automated measurement of lesion invasion depth and tumor volume
Nodular BCC with AI-placed image markers

VivoSight OCT imaging has been validated through >500 peer-reviewed publications and is in use in leading research and clinical centers internationally

  • Shown to be non-inferior to regular care punch biopsy in the diagnosis and treatment of basal cell carcinoma1
  • Improved diagnostic accuracy of OCT for NMSC compared with conventional clinical exam plus Dermoscopy2
  • OCT imaging provides complete visualisation, whereas biopsies do not always represent the entire lesion1
  • Quicker to perform than other imaging techniques such as Reflectance Confocal Microscopy2

Using VivoSight Dx OCT imaging, regular monitoring of new treatment efficacy becomes quick and simple.  Rapid tumour visualisation and quantification will support treatment efficacy validation and enhance publications.

To learn more, schedule your online Product Demonstration today

VivoSight Dx measurements are for Investigational Use only

Schedule your online demonstration.

Schedule Your Demo | Landing Page (#15)

1Adan, F. et.al.. Optical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial. Lancet Oncol. 2022; 23(8):1087-1096

2Hobelsberger, S. et.al.. Comparison of optical coherence tomography and in vivo reflectance confocal microscopy with dermoscopy for the diagnosis and management of nonmelanoma skin cancer: A randomized controlled trial. JEADV Clin Pract. 2023;1–14